Table 1 Study Patient Characteristics
Authors (reference) | Pub. Date | Average patient age (years) | Per cent Male | BSCr (mg/dl) | Diabetes (%) | Contrast volume (ml) | Jadad Score | End point (SCr rise) | Contrast procedure | NAC regimen | Hydration regimen |
|---|---|---|---|---|---|---|---|---|---|---|---|
Tepel et al. [10] | 07/00 | 65 | NA | 2.5 | 32.5 | 75 | 1 | 0.5 mg/dl 48 h | CT | 600 mg tablet bid × 4 | 0.45% 1 ml/kg/h 12 h before, 12 h after |
Diaz-Sandoval et al. [11] | 02/02 | 73 | 80% | 1.6 | 38.9 | 184 | 2 | 0.5 mg/dl or 25% 48 h | LHC | 600 mg liquid in ginger ale bid × 4 | 0.45% 1 ml/kg/h 2–12 h before, 12 h after |
Briguori et al. [12] | 07/02 | 64 | 86% | 1.5 | 37.8 | 197 | 1 | 25% 48 h | LHC and/or PA and/or PCI | 600 mg tablet bid × 4 | 0.45% 1 ml/kg/h 12 h before, 12 h after |
Vallero et al. [13] | 09/02 | 62 | NA | 1.0 | 23.0 | 205 | 1 | 0.5 mg/dl or 33% 48 h | LHC and/or PCI | 600 mg tablet bid × 4 | 0.45% 1 ml/kg/h 1–2 h before, 24 h after |
Shyu et al. [14] | 10/02 | 70 | 68% | 2.8 | 63.5 | 117 | 1 | 0.5 mg/dl 48 h | LHC ± PCI | 400 mg powder bid × 4 | 0.45% 1 ml/kg/h 12 h before, 12 h after |
Allaqaband et al. [15] | 11/02 | 70 | NA | 2.1 | 48.3 | 122 | 3 | 0.5 mg/dl 48 h | LHC ± PCI or PA + PCI | 600 mg liquid in cola bid × 4 | 0.45% 1 ml/kg/h 12 h before, 12 h after |
Durham et al. [16] | 12/02 | 71 | 66% | 2.3 | 48.1 | 81 | 3 | 0.5 mg/dl 48 h | LHC | 1200 mg liquid in orange juice bid × 2 | 0.45% 1 ml/kg/h ≤ 12 h before, ≤ 12 h after |
Kay et al. [17] | 02/03 | 69 | 62% | 1.3 | 37.5 | 125 | 5 | 25% 48 h | LHC and/or PCI | 600 mg tablet bid × 4 | 0.9% 1 ml/kg/h 12 h before, 6 h after |
Loutrianakis et al. [18] | 03/03 | 67 | NA | 1.9 | 36.0 | 147 | 1 | 0.5 mg/dl 120–168 h | LHC | 600 mg bid × 4 | 0.45% 1 ml/kg/h |
Azmus et al. [19] | 07/03 | 67 | 59% | 1.3 | 49.6 | 126 | 5 | 0.5 mg/dl or 25% 24–48 h | LHC or PCI | 600 mg powder in water bid × 5 | 0.9% 1 L pre, 1 L post, or none |
Gomes et al. [20] | 10/03 | 65 | 59% | 1.3 | 51.9 | 103 | 4 | 0.5 mg/dl 48 h | LHC or PCI | 600 mg bid × 4 | 0.9% 1 ml/kg/h 12 h before, 12 h after |
Nguyen-Ho et al. [21] | 11/03 | 70 | NA | 1.4 | 67.5 | 347 | 4 | 25% 48–72 h | LHC or PCI | 2000 mg liquid in juice bid × 2 or 3 | 0.45% 75 ml/h ≥ 24 h from enroll |
Efrati et al. [22] | 12/03 | 67 | 90% | 1.5 | 52.9 | 140 | 2 | 25% 24–96 h | LHC | 1000 mg liquid in cola bid × 4 | 0.45% 1 ml/kg/h |
El Mahmoud et al. [23] | 12/03 | 67 | 81% | 1.9 | 30.0 | 177 | 2 | 25% 24–48 h | LHC | 600 mg orally bid × 2 | 0.9% 1 ml/kg/h |
Kefer et al. [24] | 12/03 | 62 | 77% | 1.1 | 12.5 | 199 | 1 | 0.5 mg/dl or 25% 24 h | LHC and/or PCI | 1200 mg in 0.9% saline IV over 60 min, 12 h pre 0 h post | 0.9% 1 ml/kg/h |
MacNeill et al. [25] | 12/03 | 73 | 86% | 1.9 | 46.5 | 110 | 4 | 25% 72 h | LHC ± PCI | 600 mg liquid in juice/soda bid ×5 | 0.45% 1 ml/kg/h 12 h or 2 ml/kg/h 4 h before, 75 ml/h 12 h after |
Oldemeyer et al. [26] | 12/03 | 76 | 55% | 1.6 | 44.9 | 131 | 2 | 0.5 mg/dl or 25% 48 h | LHC | 1500 mg liquid in soda bid × 4 | 500 ml D5 20 ml/h 12 h before, 12 h after |
Goldenberg et al. [27] | 02/04 | 70 | 83% | 2.0 | 43.9 | 116 | 5 | 0.5 mg/dl 48 h | LHC ± PCI | 600 mg liquid in soda tid × 6 | 0.45% 1 ml/kg/h |
Agrawal et al. [28] | 04/04 | 63 | 68% | 1.7 | 47.8 | 178 | 2 | 0.5 mg/dl or 25% 48 h | LHC and/or PCI | 800/600/600 mg liquid in soda 12/2 h pre/6 h post | 0.45% 1 ml/kg 12 h ± 250 ml bolus before, 12 h after |
Fung et al. [29] | 05/04 | 68 | 70% | 2.3 | 52.8 | 128 | 3 | 0.5 mg/dl or 25% decrease in GFR 48 h | LHC or PCI ± PA | 400 mg powder tid × 6 | 0.9% 100 ml/h 12 h before, 12 h after |
Ochoa et al. [30] | 06/04 | 71 | 43% | 2.0 | 55.5 | 144 | 4 | 0.5 mg/dl or 25% 48 h | LHC and/or PCI | 1000 mg liquid in diet cola bid × 2 | 0.9% 150 ml/h, ≥ 500 ml 12 h before, ≥ 1000 24 h after |
Webb et al. [31] | 09/04 | 70 | NA | 1.7 | 34.9 | 120 | 5 | 0.5 mg/dl 48–192 h | LHC or PCI ± PA | 500 mg in D5NS IV for 15 min, 1 h pre | 0.9% 200 ml before, 1.5 ml/kg/h 6 h or discharge (<6 h) after |